沙格列汀对2型糖尿病患者血糖谱的影响

Influences of saxagliptin on blood glucose spectrum of the patients with type 2 diabetes mellitus

目的探讨沙格列汀治疗2型糖尿病患者临床疗效及安全性。方法将84例2型糖尿病患者随机分为2组,每组42例。2组均给予糖尿病常规治疗,在此基础上,对照组患者继续进行常规西药降糖治疗,研究组患者采用沙格列汀进行治疗。比较治疗前及治疗4、12周后2组患者空腹血糖(FBG)、餐后2 h血糖(2 hPG)及糖化血红蛋白(HbA1c)水平的变化,并观察体质量指数(BMI)、胰岛素抵抗指数(HOMA-IR)及肝肾功能相关指标的变化及低血糖的发生情况。结果研究组患者治疗4、12周后FBG、2 hPG水平及治疗12周后HbA1c水平均显著低于对照组,差异有统计学意义。治疗4、12周后,研究组患者HOMA-IR较治疗前明显下降,且显著低于对照组。治疗12周后,研究组患者低血糖发生情况明显减少,且显著少于对照组,差异有统计学意义。结论沙格列汀可有效降低2型糖尿病患者的血糖及HbA1c水平,提高胰岛素抵抗力,减少低血糖的发生,且安全性高。

Objective To investigate the clinical effect and safety of saxagliptin in the treat- ment of patients with type 2 diabetes mellitus （T2DM）. Methods Eighty - four patients with T2DM were randomly divided into two groups, 42 cases in each group. The patients in two groups were given routine treatment on diabetes mellitus. Based on this, those in the control group contin- ued to take routine western medicine to decrease blood glucose, while those in the research group were treated with saxagliptin. The changes of fasting blood glucose （FBG）, 2 h postprandial glu- cose （2 hPG） and glycosylated hemoglobin （HbAlc） in two groups were compared before treatment and 4, 12 weeks after treatment. Meanwhile, the changes of body mass index （BMI）, insulin resis- tance index （HOMA - IR） and the indexes related to liver and kidney function as well as hypo- glycemic incidence were also compared. Results The levels of FBG and 2 hPG 4 and 12 weeks after treatment and HbAlc level 12 weeks after treatment in the research group were significantly lower than in the control group, with significant difference. Four and 12 weeks after treatment, HOMA - IR of patients in the research group was evidently decreased compared with treatment before, and obviously lower than the control group. Twelve weeks after treatment, hypoglycemic incidence in the research group was distinctly reduced, and significantly less than the control group, with signifi- cant difference. Conclusion Saxagliptin can effectively decrease the levels of blood glucose and HbAlc in patients with T2DM, improve insulin resistance, reduce hypoglycemic incidence and has high safety.